Vanda Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VNDA Vanda Pharmaceuticals Inc
FLNT Fluent Inc
CCXI ChemoCentryx Inc
NVTA Invitae Corp
CLNE Clean Energy Fuels Corp
IMBBY Imperial Brands PLC
T AT&T Inc
JNJ Johnson & Johnson
GMS GMS Inc
TMUS T-Mobile US Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, HETLIOZ (tasimelteon) for the treatment of jet lag disorder, pediatric non-24, delayed sleep phase disorder (DSPD) and autism spectrum disorder (ASD), and Fanapt (iloperidone) for the treatment of bipolar disorder and Parkinson's disease psychosis (PDP) and a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies. VSJ-110, is for the treatment of dry eye and ocular inflammation. BPO-27, is for the treatment of secretory diarrhea disorders, including cholera. Its other product includes VQW-765.

Closing Price
$10.52
Day's Change
-0.03 (-0.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
10.70
Day's Low
10.22
Volume
(Heavy Day)
Volume:
550,814

10-day average volume:
350,766
550,814

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.